MitoThera

📖 Wiki Page

company775 wordssynced 2026-04-02

Overview

flowchart TD companies_mitothera["MitoThera"] style companies_mitothera fill:#4fc3f7,stroke:#333,color:#000 companies_mitothera_0["Pipeline Overview"] companies_mitothera -->|"includes"| companies_mitothera_0 style companies_mitothera_0 fill:#81c784,stroke:#333,color:#000 companies_mitothera_1["Lead Program: MT-101"] companies_mitothera -->|"includes"| companies_mitothera_1 style companies_mitothera_1 fill:#ef5350,stroke:#333,color:#000 companies_mitothera_2["Mechanism of Action"] companies_mitothera -->|"includes"| companies_mitothera_2 style companies_mitothera_2 fill:#ffd54f,stroke:#333,color:#000 companies_mitothera_3["Scientific Rationale"] companies_mitothera -->|"includes"| companies_mitothera_3 style companies_mitothera_3 fill:#ce93d8,stroke:#333,color:#000 companies_mitothera_4["Clinical Development"] companies_mitothera -->|"includes"| companies_mitothera_4 style companies_mitothera_4 fill:#4fc3f7,stroke:#333,color:#000 companies_mitothera_5["Technology Platform"] companies_mitothera -->|"includes"| companies_mitothera_5 style companies_mitothera_5 fill:#81c784,stroke:#333,color:#000

MitoThera is a clinical-stage biotechnology company developing mitochondria-targeted therapeutics for the treatment of neurodegenerative diseases, with a primary focus on Parkinson's disease. The company was founded in 2020 and is headquartered in San Diego, California["@mitothera"].

...

Overview

Mermaid diagram (expand to render)

MitoThera's lead program, MT-101, is a mitochondria-targeted antioxidant that specifically accumulates in the mitochondrial matrix to scavenge reactive oxygen species at their source. The company's proprietary mitochondrial targeting technology enables unprecedented delivery of therapeutic compounds to neuronal mitochondria.

Pipeline Overview

| Program | Mechanism | Indication | Phase | Status |
|---------|-----------|------------|-------|--------|
| MT-101 | Mitochondria-targeted antioxidant | Parkinson's Disease | Phase 2 | Active |
| MT-102 | Matrix-targeted SOD mimic | ALS | Phase 1 | Completed |
| MT-103 | mPTP inhibitor | Parkinson's Disease | Preclinical | IND-enabling |
| MT-201 | Mitochondrial biogenesis promoter | Alzheimer's Disease | Discovery | Research |

Lead Program: MT-101

Mechanism of Action

MT-101 is a novel mitochondria-targeted antioxidant using the company's proprietary triphenylphosphonium (TPP) cation platform:

Targeted Delivery: The TPP cation drives accumulation in mitochondria driven by the membrane potential (ΔΨm), achieving >100-fold enrichment in the mitochondrial matrix compared to cytoplasm
Antioxidant Activity: MT-101 contains a ubiquinone moiety that scavenges superoxide and other reactive oxygen species directly within the mitochondrial matrix
Redox Cycling: Unlike traditional antioxidants, MT-101 is catalytically regenerated by the electron transport chain, allowing repeated antioxidant activity
Membrane Protection: The compound helps maintain mitochondrial membrane integrity and prevents lipid peroxidation

Scientific Rationale

Mitochondrial oxidative stress is a key contributor to dopaminergic neuron death in Parkinson's disease:

Complex I Dysfunction: Impaired complex I leads to increased electron leak and superoxide production[@complex2003]
Dopamine Metabolism: Auto-oxidation of dopamine generates hydrogen peroxide and quinones[@dopamine2004]
Iron Accumulation: Elevated iron in the substantia nigra catalyzes Fenton reactions generating highly reactive hydroxyl radicals[@iron2015]

Traditional antioxidants have failed in clinical trials for PD because they do not reach therapeutic concentrations in mitochondria. MitoThera's TPP platform overcomes this limitation.

Clinical Development

MT-101 has advanced through clinical development:

Phase 1 Study (2021-2022): Single and multiple ascending dose study in 72 healthy volunteers demonstrated safety and tolerability, with dose-dependent increases in mitochondrial antioxidant biomarkers[@phase2022].

Phase 2 Study (2023-2024): A randomized, double-blind, placebo-controlled study in 150 patients with early Parkinson's disease. Results showed:

Significant reduction in markers of oxidative stress in cerebrospinal fluid
Improvement in mitochondrial function as measured by platelet bioenergetics
Favorable safety profile
Trends toward slower disease progression on MDS-UPDRS

Phase 2b/3 Trial: Planning underway for pivotal trial in early PD patients.

Technology Platform

TPP Mitochondrial Targeting

MitoThera's platform is built on the triphenylphosphonium (TPP) cation, which has been extensively validated for mitochondrial targeting:

| Component | Function |
|-----------|----------|
| TPP cation | Drives mitochondrial accumulation via membrane potential |
| Linker | Provides optimal distance for catalytic activity |
| Antioxidant moiety | Scavenges ROS in the matrix |
| Mitochondrial matrix retention | Prolongs exposure at site of action |

Advantages Over Traditional Antioxidants

| Characteristic | MT-101 | Traditional Antioxidants |
|----------------|--------|-------------------------|
| Mitochondrial concentration | >100x cytoplasmic | Similar to cytoplasmic |
| Catalytic activity | Yes (redox cycling) | No (consumable) |
| Target engagement | Direct in matrix | Indirect |
| Brain penetration | Achieved | Limited |

Mitochondrial Dysfunction in Parkinson's Disease

Pathophysiology

Mitochondrial dysfunction in PD involves multiple interconnected mechanisms:

Complex I Deficiency: 30-40% reduction in complex I activity in substantia nigra

Oxidative Stress: Elevated ROS damages proteins, lipids, and DNA

Impaired Mitophagy: Failure to remove damaged mitochondria

Altered Dynamics: Excessive fission and impaired fusion

Metabolic Deficits: Reduced glucose metabolism and ATP production

Therapeutic Target Landscape

| Target | Therapeutic Approach | Development Stage |
|--------|---------------------|-------------------|
| Mitochondrial ROS | Antioxidants (MT-101) | Phase 2 |
| Mitophagy | PINK1-Parkin activators | Phase 1 |
| mPTP opening | Pore inhibitors | Preclinical |
| Mitochondrial biogenesis | PGC-1α activators | Discovery |

Corporate Information

Headquarters: San Diego, California, USA
Founded: 2020
Funding: Series A ($35M, 2021), Series B ($65M, 2023)
Investors: ARCH Venture Partners, Versant Ventures, Pfizer Ventures

Cross-References

[Parkinson's Disease](/diseases/parkinsons-disease)
[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
[Mitochondrial Antioxidants](/mechanisms/mitochondrial-antioxidants)

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov) - Clinical trial database
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Scientific literature

References

Unknown, MitoThera Corporate Website (n.d.)

[Unknown, Complex I deficiency in PD (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12546656/)

[Unknown, Dopamine oxidation and oxidative stress (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/14676321/)

[Unknown, Iron accumulation in PD (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25877818/)

[Unknown, Phase 1 study of mitochondria-targeted antioxidant (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)

📖 View canonical wiki page →

MitoThera

Overview

Overview

Pipeline Overview

Lead Program: MT-101

Mechanism of Action

Scientific Rationale

Clinical Development

Technology Platform

TPP Mitochondrial Targeting

Advantages Over Traditional Antioxidants

Mitochondrial Dysfunction in Parkinson's Disease

Pathophysiology

Therapeutic Target Landscape

Corporate Information

Cross-References

See Also

External Links

References